Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 25, 2013

View Archived Issues

AstraZeneca details discovery of AZ7732, a new dimeric pan-IAP inhibitor

FDA approves phase I trial of ZYDPLA-1 for type 2 diabetes

BioLineRx inlicenses BL-9020 for type 1 diabetes

BPR-0C-305 displays oncolytic activity when administered orally

Panacela signs contract with Russian government for development of Mobilan anticancer vaccine

Coare Biotech receives NIH grant to develop treatment for pancreatic cancer

Mesoblast, Intrexon and Ziopharm enter partnership to develop new class of anticancer therapeutics

Beactica expands collaboration with Boehringer Ingelheim

Health Diagnostic Laboratory acquires U.S. license for Oncimmune's early lung cancer detection test

Application filed for additional indication of oral hypoglycemic agent in Japan

FDA grants priority review to Lilly's ramucirumab BLA

Bayer Schering Pharma introduces new PET radiopharmaceuticals

Merck KGaA prepares new MetAP 2 inhibitors for cancer and other disorders

GSK submits NDA for fluticasone furoate monotherapy

ImmunoGen begins phase I trial of IMGN-289

Orion Corp. patents novel alpha2A-adrenoceptor agonists

Scientists at Roche present new GPBA receptor agonists

Spanish researchers synthesize novel prostanoid EP1 receptor ligands

Cornerstone Pharmaceuticals begins phase II study of CPI-613 in SCLC

FDA awards 15 grants to support drug and device development for rare diseases

Novel calpain-1 inhibitors presented by AbbVie

Antibody-drug conjugate MLN-0264 targets GC-C expressed in pancreatic cancer

Bellus Health out-licenses Vivimind and BLU-8499

Auxilium begins phase IIa study of Xiaflex for treatment of cellulite

ManNAc safe and well tolerated in phase I study in hereditary inclusion body myopathy

FDA grants breakthrough therapy designation to Alexion's synthetic cPMP for rare genetic disorder

NPS Pharmaceuticals files Natpara BLA for hypoparathyroidism

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...